Sensitivity to experiencing alcohol hangovers : reconsideration of the 0.11% Blood Alcohol Concentration (BAC) threshold for having a hangover

Autor: Verster, JC, Kruisselbrink, LD, Slot, KA, Anogeianaki, A, Adams, S, Alford, C, Arnoldy, L, Ayre, E, Balikji, S, Benson, S, Bruce, G, Devenney, LE, Frone, MR, Gunn, C, Heffernan, T, Hensel, KO, Hogewoning, A, Johnson, SJ, van Lawick van Pabst, AE, van de Loo, AJAE, Mackus, M, Merlo, A, Murphy, RJL, Owen, LJ, Palmer, EOC, van Rossum, CJI, Scholey, A, Terpstra, C, Vatsalya, V, Vermeulen, SA, van Wijk, M, Stock, AK

Publikováno v: Journal of Clinical Medicine, Vol 9, Iss 1, p 179 (2020)
Journal of Clinical Medicine

The 2010 Alcohol Hangover Research Group consensus paper defined a cutoff blood alcohol concentration (BAC) of 0.11% as a toxicological threshold indicating that sufficient alcohol had been consumed to develop a hangover. The cutoff was based on prev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f57c5003b9c62ff49d933e28cf1294c4
https://usir.salford.ac.uk/id/eprint/56189/1/jcm-09-00179.pdf

Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover.

Autor: Verster JC; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands.; Institute for Risk Assessment Sciences (IRAS), Utrecht University, 3584CM Utrecht, The Netherlands.; Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia., Kruisselbrink LD; Centre of Lifestyle Studies, School of Kinesiology, Acadia University, Wolfville, NS B4P 2R6, Canada., Slot KA; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Anogeianaki A; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Adams S; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath BA2 7AY, UK., Alford C; Psychological Sciences Research Group, University of the West of England, Bristol BS16 1QY, UK., Arnoldy L; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Ayre E; Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia., Balikji S; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Benson S; Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia., Bruce G; Education and Social Sciences, University of the West of Scotland, Paisley PA1 2BE, UK., Devenney LE; School of Psychology, Life and Health Sciences, Ulster University, Coleraine, Co. Londonderry BT52 1SA, UK., Frone MR; Department of Psychology, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA., Gunn C; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath BA2 7AY, UK., Heffernan T; Department of Psychology, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK., Hensel KO; Cambridge Biomedical Campus, Department of Paediatrics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Faculty of Health, Department of Paediatrics, Center for Clinical & Translational Research (CCTR), Witten/Herdecke University, 58455 Witten, Germany., Hogewoning A; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Johnson SJ; Psychological Sciences Research Group, University of the West of England, Bristol BS16 1QY, UK.; Centre for Trials Research, Cardiff University, Cardiff CF14 4YS, UK., van Lawick van Pabst AE; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., van de Loo AJAE; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Mackus M; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Merlo A; Education and Social Sciences, University of the West of Scotland, Paisley PA1 2BE, UK., Murphy RJL; Centre of Lifestyle Studies, School of Kinesiology, Acadia University, Wolfville, NS B4P 2R6, Canada., Owen L; Department of Psychology, School of Health and Society, University of Salford, Salford 5 M6 6PU, UK., Palmer EOC; Department of Medicine, Imperial College London, London W12 0NN, UK., van Rossum CJI; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Scholey A; Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia., Terpstra C; Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia., Vatsalya V; Department of Medicine, University of Louisville, Louisville, KY 40202, USA.; Alcohol Research Center, University of Louisville, Louisville, KY 40202, USA.; Hepatobiology & Toxicology Center, University of Louisville, Louisville, KY 40202, USA.; National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD 20892, USA.; Robley Rex Louisville VAMC, Louisville, KY 40206, USA., Vermeulen SA; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., van Wijk M; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584CG Utrecht, The Netherlands., Stock AK; Cognitive Neurophysiology Department of Child and Adolescent Psychiatry, Faculty of Medicine of the TU Dresden, University of Dresden, D-01307 Dresden, Germany.

Publikováno v: Journal of clinical medicine [J Clin Med] 2020 Jan 09; Vol. 9 (1). Date of Electronic Publication: 2020 Jan 09.

Dihydromyricetin Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line: Role of GABAA Receptor.

Autor: Getachew, Bruk¹ (AUTHOR), Csoka, Antonei B.² (AUTHOR), Tizabi, Yousef¹ (AUTHOR) ytizabi@howard.edu

Publikováno v: Neurotoxicity Research. Jun2022, Vol. 40 Issue 3, p892-899. 8p.